In Brief: Becton Dickinson
This article was originally published in The Gray Sheet
Becton Dickinson: Firm's goal of doubling the size of the company within five years will likely include acquisitions aimed at broadening its core businesses, which include injection systems, vascular access devices, flow cytometry technology, infectious disease diagnostics, sample collection and tissue culture products, the company says. Growth also will come through geographic expansion, such as in the Asia-Pacific region ("The Gray Sheet" Aug. 11, I&W-11), and internal product development. Over the next several years BD plans to increase the percentage of revenues it derives from products introduced within the previous three years to 25% from 15%. In addition, the company has set a target of achieving 10% annual revenue growth by the year 2000...
You may also be interested in...
The AAM has insisted that the US Supreme Court should uphold the inter partes review framework, in an amicus brief filed as part of litigation that potentially threatens hundreds of IPR decisions.
The US is to ship only half of doses for Pfizer, Moderna COVID-19 vaccines in the first instance, while Rhizen Pharmaceuticals starts a Phase I trial of a DHODH inhibitor.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.